Search hospitals > Minnesota > Burnsville

M Health Fairview Ridges Hospital

Claim this profile
Burnsville, Minnesota 55337
Conducts research for Stroke
Conducts research for Coronavirus
Conducts research for Ischemic Stroke
Conducts research for COVID-19
Conducts research for Respiratory Distress Syndrome
4 reported clinical trials
1 medical researcher
Photo of M Health Fairview Ridges Hospital in BurnsvillePhoto of M Health Fairview Ridges Hospital in BurnsvillePhoto of M Health Fairview Ridges Hospital in Burnsville

Summary

M Health Fairview Ridges Hospital is a medical facility located in Burnsville, Minnesota. This center is recognized for care of Stroke, Coronavirus, Ischemic Stroke, COVID-19, Respiratory Distress Syndrome and other specialties. M Health Fairview Ridges Hospital is involved with conducting 4 clinical trials across 12 conditions. There are 1 research doctors associated with this hospital, such as Christopher Streib, MD.

Top PIs

Clinical Trials running at M Health Fairview Ridges Hospital

Stroke
Ischemic Stroke
Image of trial facility.

Milvexian

for Stroke

This trial is testing whether milvexian can help prevent another stroke in people who have already had one by stopping blood clots from forming. Milvexian may reduce the risk of stroke without significant bleeding.
Recruiting1 award Phase 35 criteria
Image of trial facility.

Recombinant Factor VIIa

for Hemorrhagic Stroke

The objective of the rFVIIa for Acute Hemorrhagic Stroke Administered at Earliest Time (FASTEST) Trial is to establish the first treatment for acute spontaneous intracerebral hemorrhage (ICH) within a time window and subgroup of patients that is most likely to benefit. The central hypothesis is that rFVIIa, administered within 120 minutes from stroke onset with an identified subgroup of patients most likely to benefit, will improve outcomes at 180 days as measured by the Modified Rankin Score (mRS) and decrease ongoing bleeding as compared to standard therapy. FASTEST Part 2 is an extension of the FASTEST Trial where the subgroups include only those treated within 2 hours with a positive spot sign on a baseline CT angiogram.
Recruiting1 award Phase 32 criteria
Image of trial facility.

rFVIIa

for Hemorrhagic Stroke

The objective of the rFVIIa for Acute Hemorrhagic Stroke Administered at Earliest Time (FASTEST) Trial is to establish the first treatment for acute spontaneous intracerebral hemorrhage (ICH) within a time window and subgroup of patients that is most likely to benefit. The central hypothesis is that rFVIIa, administered within 120 minutes from stroke onset with an identified subgroup of patients most likely to benefit, will improve outcomes at 180 days as measured by the Modified Rankin Score (mRS) and decrease ongoing bleeding as compared to standard therapy.
Recruiting1 award Phase 34 criteria

Similar Hospitals nearby

Frequently asked questions

What kind of research happens at M Health Fairview Ridges Hospital?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security